Table 1.
Individual variables obtained from ROC analysis for differentiation of LAPs from metastases.
| Variables | Cutoff | AUC | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|
| Age | 59.5 | 0.630 | 62.6% | 62.7% | 63.6% | 61.7% |
| CT values in UP | 27.5 | 0.789 | 92.7% | 57.6% | 69.5% | 88.3% |
| ERA | 1.04 | 0.795 | 78.9% | 69.5% | 72.9% | 75.9% |
| ERV | 1.44 | 0.805 | 82.9% | 66.1% | 71.8% | 78.8% |
| Gender | – | 0.679 | 75.6% | 60.2% | 66.4% | 70.3% |
| Shape | – | 0.552 | 16.3% | 94.1% | 74.1% | 51.9% |
| Cystic degeneration | – | 0.567 | 25.2% | 88.1% | 68.9% | 53.1% |
| Histology of lung cancer | – | 0.628 | 34.1% | 91.5% | 80.8% | 57.1% |
| Peak enhancement phase | – | 0.651 | 96.7% | 22.3% | 56.4% | 86.7% |
| Clinical stage of lung cancer | – | 0.710 | 91.9% | 39.0% | 61.1% | 82.1% |
ROC, receiver operating characteristic curve; UP, unenhanced phase; ERA, enhancement ratio on arterial phase; ERV, enhancement ratio on venous phase; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.